Okafor Michael 1,2*, Okoli Uzoamaka 1,2, Germaine Adaugo Ohadugha3, Elvis Naba Shu1 and Anusiem Chikere1

1 Department of Pharmacology and therapeutics, College of Nigeria, University of Nigeria;
2 Basic and Translational Cancer Research, College of Medicine, University of Nigeria
3 Department of Orthopedic Surgery, Lagos University Teaching Hospital, Nigeria

*Corresponding author: Michael.okafor@unn.edu.ng
Cannabis as Medicine: Pros and Cons

Δ⁹-Tetrahydrocannabinol

Cannabinol

CB1 receptor
CB2 receptor

Pharmacogenetics: diverse population with different human disorders

GENES
- CNR1,
- CNR2,
- TRPV1
- GPR55,
- GABRA2
- OPRM1,
- etc
Abstract: The use of cannabis for medical reasons is surrounded by numerous pharmacological dilemmas. However, its use in modern day medicine is here to stay. Complexity of the cannabinoid pathway as well as individual genetic predisposition is responsible for different body responses on cannabinoid treatment. Knowledge of cannabinoid receptors and their polymorphisms should enable prediction of patients with gene variations coding these receptors via gene expression studies. Pros of its use as medicine is also undermined by cons. This is further compounded by paucity of literature which highlight the association of genetics with side effects of cannabis use.

Aim: To discuss the pharmacogenetics of cannabis on cannabinoid receptors to highlight receptors that can be screened via gene expression studies in order to better profile patients for medical marijuana.

Methods: Online searches on the following database; Google Scholar, PubMed, Biomed Central and SciEELL was done. Attempts were made to review articles with keywords; cannabis, cannabinoid receptors, gene profiling and medical marijuana.

Conclusion: Medical profiling via cannabinoid gene expression studies of patients who are medical candidates of cannabis should prevent negative effects associated with its medical use.

Keywords: Cannabinoid receptors, gene expression
Introduction

• Cannabis remains the most widely used drug globally, with an estimated 188 million people having used the drug. It was estimated that 5.5 per cent of the global population aged 15-64 had used cannabis (UNODC, 2019).

• Cannabis plant is a plant used for its psychoactive or medicinal properties.

• Cannabis sativa is the source of a set of compounds known collectively as phytocannabinoids or plant cannabinoids.

• The cannabis plant contains about 540 chemical substances.

• The main cannabinoids are Tetrahydrocannabinol (THC) and Cannabinol (CBD)
• Medicinal cannabis is sometimes referred to as medicinal marijuana, but they are practically not the same because marijuana contains more of the psychoactive agent which is the Delta 9 tetrahydrocannabinoid - $\Delta^9$THC acts on cannabinoid1 (CB1) receptor (Bostwick et al., 2013).

• The second cannabidiol (CBD) acts on cannabinoid 2 (CB2) receptor and lacks psychoactivity but works in synergy with $\Delta^9$-THC to minimize “highs” maximize analgesic properties (Bostwick et al., 2013).

• Although Cannabis plant has not been approved for medical use. several drugs that contain individual cannabinoids have been approved by FDA

---

### Table 1: Approved FDA Cannabis and Cannabis product

<table>
<thead>
<tr>
<th>Cannabis Product</th>
<th>Active ingredient (and Pharmaceutical formulation)</th>
<th>Therapeutic Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epidiolex,</td>
<td>Purified CBD, (Oral)</td>
<td>Severe forms of epilepsy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Lennox-Gastaut syndrome</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Dravet syndrome</td>
</tr>
<tr>
<td>Marinol</td>
<td>Dronabinol (synthetic $\Delta^9$THC) (Oral gelatinous gel capsules formulated in sesame oil) (Oral solution)</td>
<td>Loss of appetite and Anorexia - weight loss in people with HIV/AIDS.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Nausea and vomiting induced chemotherapy</td>
</tr>
<tr>
<td>Syndros</td>
<td></td>
<td>treat nausea and vomiting caused by cancer chemotherapy</td>
</tr>
<tr>
<td>Cesamet</td>
<td>Nabilone (synthetic $\Delta^9$THC) and dibenzopyrane derivative (Oral off-white polymorphic crystalline powder)</td>
<td>• antiemetic and as adjuvant analgesic for neuropathic pain,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• chronic pain management</td>
</tr>
</tbody>
</table>
Results and discussion

The cannabinoid receptors on activation by the binding of specific ligands inhibit the adenyl cyclase, protein phosphorylation and certain voltage dependent calcium channels (VDCC). This process is cAMP- dependent and leads to the activation of mitogen activating protein kinase (MAPK). MAPK modulates the G- protein coupled Ca\(^+\) and K\(^+\) channels (causing inward arrangement of K\(^+\) channels). AEA, 2AG, N- Arachidonoyl – dopamine (NADA) act at vanilloid receptor (transient receptor potential vanilloid type 1, TRPV1, a ligand gated channel.)
Highlights of Cannabinoids Pharmacogenetics

• The effect of medical cannabis can be elucidate by knowledge of its pharmacogenetics in individual human organism. Knowledge based on molecules and the proteins involved in the transport, mechanism of action, and metabolism of cannabinoids can lead to prediction of variations in human genes that are responsible for the therapeutic and adverse effects of medical cannabinoid-based drugs (Hryhorowicz et al., 2018; Onaivi, 2009).

• The group of genes involved are

  ➢ CNR1, CNR2, TRPV1, encoding CB1, CB2 and TRPV receptors respectively. Other receptor genes include GPR55, GABRA2 and OPRM1.

  ➢ The transporter genes and genes involved in metabolism of cannabinoids ABCB1, ABCG2, SLC6A4, and COMT;

  ➢ enzymes involved in the metabolism of cannabinoids CYPs and UGTs;

  ➢ biosynthesis of endocannabinoids FAAH, COX2, MAGL, ABHD6, and ABHD12; and cannabinoid-related cellular signalling processes: MAPK14. (Atakan, 2012; Hryhorowicz et al., 2018; Onaivi, 2009).
Short nucleotide polymorphism (SNP) various in genes encoding the endocannabinoids, cannabinoids have been associated with different human disorders. Polymorphism of CNR1 and CNR2 genes have been associated with human disorders including, posttraumatic stress disorder (PTSD), drug dependency, osteoporosis, obesity, depression and ADHD (Onaivi, 2009)
Conclusion

In conclusion, in situations where conservative options with minimal success, patients may benefit from the potential relief that medical cannabis affords. Further well-powered studies are required to resolve the pressing dilemma.
References

Acknowledgement

• Special thanks to;

Dr. Uzoamaka Okoli, Dr Ohadugha
Basic and Translational Cancer research Group, College of Medicine, University of Nigeria Nsukka.

Rev Prof. Anusiem and Prof Shu
Department of Pharmacology and Therapeutics, Faculty of Medical Sciences, College of Medicine. University of Nigeria Nsukka